In its first-quarter 2025 investor letter, Carillon Eagle Mid Cap Growth Fund highlighted stocks such as Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is a pharmaceutical products distributor.

In its first-quarter 2025 investor letter, Carillon Eagle Mid Cap Growth Fund highlighted stocks such as Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is a pharmaceutical products distributor.

Shares of Cencora Inc. COR rallied 1.24% to $285.90 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.74% to 5,525.21 and ...

Cencora COR has outperformed the market over the past 5 years by 12.25% on an annualized basis producing an average annual return of 25.82%. Currently, Cencora has a market capitalization of $55. ...

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. Growth stocks are ...

Valued at a market cap of $54.8 billion, Cencora, Inc. (COR) is a global healthcare solutions provider. Headquartered in Conshohocken, Pennsylvania, the company specializes in sourcing and ...

We benefited from Cencora, Inc. (COR), which distributes pharmaceutical and medical products to pharmacies, hospitals, and other health care providers. Cencora’s revenues and earnings each ...

The deal, valued at $280 million, aims to establish a comprehensive cancer care network in the state. 6. In November 2024, Cencora reached a definitive agreement to acquire Retina Consultants of ...